<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix Announces Receipt of CLIA Registration Number

    October 31, 2008

    Biodesix, Inc., is pleased to announce receipt of a CLIA registration which allows the company to commercially market Veristrat® .

    Biodesix Announces VeriStrat® Data in Head and Neck Cancer to be Presented at ASCO

    May 14, 2009

    Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University will be presenting data on Veristrat at the 45th Annual Meeting of ASCO.

    Biodesix Names Paul J Beresford, Formerly of Roche Diagnostics, as Vice President, Business Development and Stategic Marketing

    December 5, 2008

    Biodesix announced that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing.

    New Data from Phase III Lung Cancer Trial Show VeriStrat® Identifies Patients Likely to Respond to Erlotinib

    May 6, 2010

    Phase III trial shows that VeriStrat identified patients likely to respond to erlotinib (Tarceva.)

    VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    April 19, 2010

    Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.

    Biodesix Names Douglas E. Swan, formerly of Imclone Systems Incorporated, as Vice President, Commercial Operations

    October 1, 2008

    Biodesix announced today that Douglas E. Swan has joined the company as Vice President, Commercial Operations, reporting directly to David Brunel, CEO

    Biodesix Advances the Field of Personalized Medicine with the Launch of VeriStrat®

    May 5, 2009

    Biodesix announces the U.S. commercial availability of VeriStrat.

    Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    February 5, 2010

    Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.

    Biodesix Secures $10 Million in Series B-1 Funding

    September 28, 2009

    Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.
    5 6 7 8 9 10 11 12 13